AcquisitionOther

Ikena Oncology, Inc. acquired target

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Ikena Oncology, Inc. -> target · $75 million

“In our search for the right partner for Ikena, Inmagene’s IMG-007 differentiated clinical data in atopic dermatitis and potential as a pipeline in a product across the I&I space was a compelling fit,” commented Mark Manfredi, PhD, Chief Executive Officer of I

Open source record (SEC) ↗